Anti-CD79b Top1i ADCs for Targeted B-Cell Lymphoma Cytotoxicity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for developing potent anti-CD79b Top1i ADCs that provide targeted delivery in treating B-cell malignancies, as existing therapies may not effectively utilize the CD79b antigen for targeted cytotoxicity against B-cell non-Hodgkin lymphomas.

Innovation Solution

The development of anti-CD79b antibodies conjugated with a Top1i drug through a linker, forming anti-CD79b Top1i ADCs, which specifically target CD79b-expressing B-cell malignancies, utilizing specific CDR sequences and linker-drug configurations to enhance therapeutic efficacy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing therapies are used to treat B-cell malignancies, then treatment is provided, but the therapies do not effectively utilize the CD79b antigen for targeted cytotoxicity

Engineering Contradiction:

Improvetargeted cytotoxicity efficacyVSAvoidantigen utilization

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The therapy is segmented into distinct functional components: an anti-CD79b antibody fragment for specific antigen recognition and binding, a linker for controlled drug delivery, and a cytotoxic payload for tumor cell destruction. This segmentation allows each component to be optimized for its specific function, enabling effective utilization of the CD79b antigen for targeted cytotoxicity.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The anti-CD79b antibody serves as an intermediary that bridges the cytotoxic payload and the CD79b antigen on B-cell malignancy cells. This intermediary enables specific recognition and binding to the target antigen, directing the cytotoxic effect precisely to tumor cells while sparing healthy tissues.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If anti-CD79b Top1i ADCs are developed with specific CDR sequences and linker-drug configurations, then therapeutic efficacy is enhanced, but the complexity of the antibody structure increases

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidantibody structure complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The antibody structure incorporates specific local qualities through defined CDR sequences (VH-CDR1: NYWIT, VH-CDR2: NINQAGSEKSYLDAVKG, VH-CDR3: GFRAFDI, VL-CDR1: RSSQSLLHSSGESYLD, VL-CDR2: LGSHRAS, VL-CDR3: MQALQTPLT) that are optimized for CD79b binding affinity and specificity. The linker-drug configuration also employs local quality optimization with specific chemical structures designed for controlled drug release. This localized optimization enhances therapeutic efficacy without requiring complete redesign of the entire antibody structure.

Inventive Principle:

Principle #3Local quality

Data Source

PatentEP4670742A1Anti-CD79b antibody drug conjugates

Publication Date: 2025.12.31 ABBVIE INC

Figure 1
Figure 2

AI summary

The present disclosure relates to anti-CD79b antibodies and anti-CD79b antibody drug conjugates (anti-CD79b ADCs) comprising thereof, where the anti-CD79b ADCs further comprise a topoisomerase 1 inhibitor (Topli) drug as a payload. The present disclosure further relates to methods of using such anti-CD79b ADCs for treating B-cell non-Hodgkin lymphoma (B-NHL), diffuse large B cell lymphoma (DLBCL), Burkitt's lymphoma, mantle cell lymphoma, and follicular lymphoma.